中文摘要：

卵巢癌化疗多药耐药（multidrugresistance，MDR）的发生和发展是多基因参与的极其复杂的过程，其发生机制目前尚不十分明确。既往的研究着重在开发小分子抑制剂靶向多药耐药基因编码的P-糖蛋白逆转多药耐药，但效果不佳。本文总结了近年来对卵巢癌多药耐药发生机制的研究进展以及克服卵巢癌治疗中MDR问题的新方案，包括新型的P-糖蛋白抑制剂，靶向肿瘤干细胞和微小核糖核酸（miRNAs），自噬信号通路调节等，为临床卵巢癌多药耐药的治疗提供参考。

英文摘要：

The development of multidrug resistance （MDR） in ovarian cancer is a complicated process involved many genes. Previous research has mainly focused on targeting the MDR1 gene encoded P-glycoprotein （P-gp） with small molecular inhibitors to reverse MDR, but the results showed not good. This review summarizes the novel mechanisms of MDR and new strategies to overcome MDR in ovarian cancer, including new P-gp inhibitors, targeting CSCs and miRNAs, modulating autophagy-signaling pathway.